Home / Health / Health Canada Approves Oral Weight-Loss Drug

Health Canada Approves Oral Weight-Loss Drug

Summary

  • A new daily pill called Foundayo is now approved for weight loss.
  • Foundayo works differently than injectable GLP-1 medications.
  • Gastrointestinal issues are common side effects of GLP-1 drugs.
Health Canada Approves Oral Weight-Loss Drug

A new oral medication for weight loss, Foundayo, has received Health Canada authorization on November 13, 2026. This daily pill, developed by Eli Lilly, is approved for adults who are obese or overweight with at least one related health issue, such as high blood pressure or sleep apnea. It is also indicated for the treatment of Type 2 diabetes. Foundayo's active ingredient, orforglipron, functions as a GLP-1 receptor agonist.

Unlike larger peptide-based injectables like semaglutide and tirzepatide, orforglipron's smaller molecular structure allows it to be taken orally. Experts suggest it may be as effective as, or even more so than, existing injectable GLP-1 medications for weight loss. Gastrointestinal issues, including nausea and vomiting, are the most frequently reported side effects for this class of drugs.

Eli Lilly anticipates Foundayo will be available in Canadian pharmacies by January 2027. This development follows the success of injectable GLP-1 drugs and offers a potentially more convenient option for many patients. Novo Nordisk is also seeking Health Canada approval for its own GLP-1 weight-loss pill, potentially offering another oral alternative in the near future.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571